我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
29
1 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
1950
进行中（未招募）
1
3.5%
已完成
23
79.3%
招募中
3
10.3%
暂无批准数据
- Zenyaku Kogyo and Chugai Pharmaceutical announced that Rituxan (rituximab) received regulatory approval from Japan's MHLW for treating autoimmune hemolytic anemia on February 19, 2026. - The approval follows a public knowledge-based application process initiated by Japanese hematology societies, with the application submitted in August 2025 after regulatory committee evaluations. - Autoimmune hemolytic anemia is designated as an intractable disease in Japan, with approximately 80% of warm AIHA patients showing improvement with steroids but facing common recurrence issues. - Rituxan's anti-CD20 mechanism targets B cells that produce autoantibodies, offering a therapeutic option for patients with relapsed or refractory disease where current treatments have limitations.
